Analysers at the cutting edge of practice
Sepsis affects 26 million people worldwide every year, and is increasing at a rate of 1.5% annually. Timely and accurate detection in the acute-care setting is key to halting the progression of the condition. Beckman Coulter has announced that its Early Sepsis Indicator (ESId), available on the recently launched DX 900 haematology analyser, has received CE-marking and also clearance from the US Food and Drug Administration. The ESId is the first early sepsis warning solution to be offered as part of a routine full blood count (FBC) with differential test.
This story is Premium Content and is only available to registered users. Please log in to view the full text. If you don't already have an account, please register with us completely free of charge.